Literature DB >> 775620

Determination of varicella immunity by the indirect immunofluorescence test in urgent clinical situations.

M Grandien, P Appelgren, A Espmark, K Hanngren.   

Abstract

Certain categories of patients run an increased medical risk when exposed to varicella. Newborns lacking maternal immunity, immunosuppressed leukemic children or children with other immunodeficient disorders may gain a decisive benefit by administration of e.g. interferon or of specific immunoglobulin against varicella. An indirect immunofluorescence (IF) method has been used to estimate varicella. An indirect immunofluorescence (IF) method has been used to estimate varicella immunity. Of 51 heavily exposed women denying earlier varicella, 39 were found to be immune by the test and none of those contracted varicella, whereas 9 out of the 12 non-immune women fell ill. 14/48 immunosuppressed children were found to be seropositive and none of these contracted varicella, whereas 13 mild or subclinical cases occurred among the 34 seronegative children. The same test revealed that 175/182 (96%) young adults in Sweden were immune. The indirect IF test is considered a rapid, simple and reliable method for estimating varicella immunity.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 775620     DOI: 10.3109/inf.1976.8.issue-2.01

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  3 in total

1.  Virus-specific immunoglobulin G subclasses in herpes simplex and varicella-zoster virus infections.

Authors:  V A Sundqvist; A Linde; B Wahren
Journal:  J Clin Microbiol       Date:  1984-07       Impact factor: 5.948

2.  Human serum antibodies to varicella-zoster virus thymidine kinase.

Authors:  C F Källander; J S Gronowitz; E G Torfason
Journal:  Infect Immun       Date:  1982-04       Impact factor: 3.441

3.  The differences in short- and long-term varicella-zoster virus (VZV) immunoglobulin G levels following varicella vaccination of healthcare workers measured by VZV fluorescent-antibody-to-membrane-antigen assay (FAMA), VZV time-resolved fluorescence immunoassay and a VZV purified glycoprotein enzyme immunoassay.

Authors:  P A C Maple; J Haedicke; M Quinlivan; S P Steinberg; A A Gershon; K E Brown; J Breuer
Journal:  Epidemiol Infect       Date:  2016-03-28       Impact factor: 2.451

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.